GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (NAS:PGNX) » Definitions » Net Change in Cash

Progenics Pharmaceuticals (Progenics Pharmaceuticals) Net Change in Cash : $-78.94 Mil (TTM As of Mar. 2020)


View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Progenics Pharmaceuticals's Net Change in Cash for the three months ended in Mar. 2020 was $-12.88 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2020 was $-78.94 Mil.

Progenics Pharmaceuticals Net Change in Cash Historical Data

The historical data trend for Progenics Pharmaceuticals's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals Net Change in Cash Chart

Progenics Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -45.20 65.12 -48.75 47.06 -94.16

Progenics Pharmaceuticals Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.09 -23.03 -20.28 -22.76 -12.88

Progenics Pharmaceuticals Net Change in Cash Calculation

Progenics Pharmaceuticals's Net Change in Cash for the fiscal year that ended in Dec. 2019 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-74.698+-15.508+-3.901+-0.048
=-94.16

Progenics Pharmaceuticals's Net Change in Cash for the quarter that ended in Mar. 2020

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-7.607+-3.553+-1.52+-0.201
=-12.88

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-78.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Progenics Pharmaceuticals Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Progenics Pharmaceuticals (Progenics Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (NAS:PGNX) » Definitions » Net Change in Cash
Comparable Companies
SELB STRO EIGR ETNB SPPI UBX OVID MNKD GERN MEIP OCSE:NOVO B ASX:CSL VRTX REGN XKRX:207940 SGEN MRNA ALXN XKRX:068270 INCY
Traded in Other Exchanges
N/A
Address
One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007
Website
http://www.progenics.com
Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.
Executives
Asha Das officer: Chief Medical Officer C/O PROGENICS PHARMACEUTICALS, INC., 1 WORLD TRADE CENTER, 47TH FL, SUITE J, NEW YORK NY 10007
Ann L. Macdougall director C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Karen Jean Ferrante director 150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Heinz Christoph Maeusli director SCHUETZENWEG 3, ENGELBURG V8 9032
Gerard Ber director C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Bradley L Campbell director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Balaji Venkataraman 10 percent owner, other: See Explanation of Responses FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Virinder Nohria 10 percent owner, other: See Explanation of Responses 1055 POWERS PLACE, SUITE B, ALPHARETTA GA 30009
Nicole Williams director
David A Scheinberg director 325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Michael D Kishbauch director 18 CHERRYVILLE RD, FLEMINGTON NJ 08822
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022

Progenics Pharmaceuticals (Progenics Pharmaceuticals) Headlines

From GuruFocus

Progenics Urges Shareholders to Reject the Risk and Uncertainty That Would be Caused by Giving Velan's Nominees Control of the Board

By Marketwired Marketwired • 11-04-2019

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Progenics Pharmaceuticals, Inc. to Lantheus Holdings, Inc. is Fair to Shareholders

By Marketwired Marketwired • 10-03-2019

Progenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program

By Marketwired Marketwired • 05-18-2020

Progenics Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Progenics Pharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – PGNX

By Marketwired Marketwired • 10-02-2019

Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Progenics Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Lantheus Holdings, Inc.

By PRNewswire PRNewswire • 10-03-2019

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigations of Mergers

By Marketwired Marketwired • 10-03-2019

Progenics Pharmaceuticals to Announce and Host a Conference Call to Discuss Top Line Results from Phase 3 CONDOR Trial of PyL™ in Prostate Cancer on Monday, December 23rd

By GlobeNewswire GlobeNewswire • 12-22-2019

PGNX, PRTO, and ARTX SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

By Marketwired Marketwired • 10-17-2019

Progenics Sends Letter to Shareholders

By Marketwired Marketwired • 10-10-2019

Progenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of Elections

By Marketwired Marketwired • 11-09-2019